Although concern remains about the athero-thrombotic risk posed by cyclo-oxygenase (COX)-2selective inhibitors, recent data implicates rofecoxib, while celecoxib appears equivalent to NSAIDs naproxen and ibuprofen. We investigated the hypothesis that celecoxib activates AMP kinase (AMPK) signalling to enhance vascular endothelial protection. In human arterial and venous endothelial cells (EC), and in contrast to ibuprofen and naproxen, celecoxib induced the protective protein heme oxygenase-1 (HO-1). Celecoxib derivative 2,5-dimethyl-celecoxib (DMC) which lacks COX-2 inhibition also upregulated HO-1, implicating a COX-2-independent mechanism. Celecoxib activated AMPKα (Thr172) and CREB-1 (Ser133) phosphorylation leading to Nrf2 nuclear translocation. Importantly, these responses were not reproduced by ibuprofen or naproxen, while AMPKα silencing abrogated celecoxib-mediated CREB and Nrf2 activation. Moreover, celecoxib induced H-ferritin via the same pathway, and increased HO-1 and H-ferritin in the aortic endothelium of mice fed celecoxib (1000 ppm) or control chow. Functionally, celecoxib inhibited TNF-α-induced NF-κB p65 (Ser536) phosphorylation by activating AMPK. This attenuated VCAM-1 upregulation via induction of HO-1, a response reproduced by DMC but not ibuprofen or naproxen. Similarly, celecoxib prevented IL-1β-mediated induction of IL-6. Celecoxib enhances vascular protection via AMPK-CREB-Nrf2 signalling, a mechanism which may mitigate cardiovascular risk in patients prescribed celecoxib. Understanding NSAID heterogeneity and COX-2-independent signalling will ultimately lead to safer anti-inflammatory drugs.
. Celecoxib induces HO-1 in human endothelium. HUVECs were treated with celecoxib (up to 10 µM) or vehicle alone for up to 24 h, followed by: (A) RNA extraction and analysis of HO-1 by qRT-PCR, and (B) protein extraction and analysis by immunoblotting for HO-1 and α-tubulin. The histogram shows corresponding densitometry data corrected for α-tubulin. Data are expressed as the mean ± SEM (n = 4 experiments) and normalized to vehicle-treated cells, *P ≤ 0.05, **P ≤ 0.01, using a one-way ANOVA with a Bonferonni correction. Immunoblots shown have been cropped to conserve space, please see Supplementary file for original uncropped blots.
SCIENTIFIC REPORTS | (2018) 8:6271 | DOI:10.1038/s41598-018-24548-z is a structural analogue of celecoxib in which the 4-methylphenyl is replaced by a 2,5-dimethylphenyl, so preventing COX-2 inhibition 22 . The response of HUVEC to DMC mirrored that seen with celecoxib, suggesting a COX-2-independent mechanism. Thus, DMC induced a 3-4-fold increase in HO-1 mRNA and protein in a concentration-dependent manner ( Fig. 2A,B ). No HUVEC toxicity was seen with either drug at concentrations up to 10 μM, while as expected cell viability began to fall when the concentration of DMC was increased to 30 μM (Supplementary Figure 1A,B) . Moreover, the presence of cycloheximide attenuated celecoxib-mediated induction of HO-1 (p < 0.001), confirming dependence upon de novo protein synthesis (Supplementary Figure 1C) .
Naproxen and ibuprofen are two of the most widely prescribed nsNSAIDs. In contrast to celecoxib and DMC, they failed to induce HO-1 in HUVEC at concentrations up to 100 μM (Fig. 2C,D) . Together these data suggest , Ad-CA-AMPK (MOI 100 ifu/cell) or left untreated for 24 h, followed by protein extraction and immunoblotting for HO-1 or α-tubulin. (C) HUVECs were treated with celecoxib (10 μM) for up to 60 mins, or (D) naproxen up to 100 μM for 15 mins, prior to protein extraction and immunoblotting for phospho-AMPK Thr172 and GAPDH. (E,F) HUVECs were left untransfected or transfected with control siRNA (CTRL) or AMPKα1 siRNA (50 nM) and cultured for 48 h prior to treatment with vehicle or celecoxib (10 µM) for 24 h and (E) analysis of HO-1 by qRT-PCR, or (F) protein extraction and immunoblotting for HO-1, total-AMPK and GAPDH. Data are expressed as the mean ± SEM of at least 3 separate experiments. The histograms show corresponding densitometry data corrected for α-tubulin or GAPDH and normalized to vehicle-treated cells. *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, using the one-way ANOVA + Bonferonni correction or a two-way ANOVA. Immunoblots shown have been cropped to conserve space, please see Supplementary file for original uncropped blots. were treated with vehicle (veh) or celecoxib (10 μM) for up to 60 mins, prior to lysis and immunoblotting for phospho-CREB Ser133 , total CREB and GAPDH. (B) Nuclear lysates, isolated from HUVEC following treatment with celecoxib 10 μM (Cele) or vehicle control for 30 mins, were analysed using a phospho-CREB transcription factor assay kit. Unstimulated Hela cells were used as a positive control (CTRL) and a wild-type oligonucleotide sequence (WT) was used for competitive binding. CREB-binding is expressed relative to vehicle-treated cells. (C,D) HUVECs were left untransfected or transfected with control siRNA (CTRL) or CREB siRNA (50 nM) and cultured for 48 h prior to treatment with vehicle or celecoxib (10 µM) for (C) 15 mins followed by immunoblotting for phospho-CREB and GAPDH, or for 24 h followed by analysis of (D) HO-1 by qRT-PCR and (E) HO-1 protein by immunoblotting. (F) HAEC were treated with celecoxib (10 μM) or vehicle for 15 mins prior to immunoblotting for: phospho-AMPK Thr172 , phospho-CREB Ser133 and GAPDH. (G) HAECs were treated with celecoxib (10 μM) or vehicle for 24 h prior to immunoblotting for HO-1. Data are expressed as the mean ± SEM of at least 3 separate experiments. The histograms show corresponding densitometry data corrected for α-tubulin or GAPDH and normalized to vehicle-treated cells. *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, using the one-way with a Bonferonni correction or two-way ANOVA (A-E) and a one-sample t-test. (F,G) Immunoblots shown have been cropped to conserve space, please see Supplementary file for original uncropped blots. Celecoxib-mediated activation of AMPKα induces endothelial HO-1. Given that AMPK agonist AICAR increased endothelial HO-1 to a level approaching that seen in response to the positive control hemin (protoporphyrin IX) ( Fig. 3A) 23 , and in light of our data linking AMPK activation to HO-1 expression in human EC 24 , we investigated AMPK as a celecoxib signalling intermediary. First, the 3-4-fold induction of HO-1 seen in response to AICAR was reproduced by transfection of HUVEC with an adenoviral vector expressing constitutively-active AMPK (Fig. 3A,B ). Treatment of HUVEC with celecoxib for up to 60 mins led to a 2-fold increase in AMPKα activation, as evidenced by phosphorylation at Thr 172 which was maximal after 15 mins ( Fig. 3C ). Of note, neither exposure to naproxen ( Fig. 3D ), nor treatment with ibuprofen ( Supplementary  Figure 2A ) led to a significant increase in AMPKα phosphorylation.
Next, a loss of function approach using validated siRNA 24, 25 was adopted to demonstrate the role of AMPKα. Exposure of HUVEC to celecoxib for 24 h increased total AMPKα by 70%, while protein expression in untreated and celecoxib-treated cells was significantly reduced by AMPKα siRNA (p < 0.001, Supplementary Figure 2B ). The induction of HO-1 mRNA by celecoxib in EC depleted of AMPKα was completely attenuated (p < 0.001, Fig. 3E ). Similarly, the increase in HO-1 protein was inhibited by AMPKα silencing, while control siRNA had no significant effect ( Fig. 3F ).
Celecoxib induction of HO-1 involves an AMPK-CREB-dependent pathway.
To investigate further the transcriptional pathway regulating HO-1 induction by celecoxib, cyclic AMP-response element binding protein (CREB) was identified as a potential candidate. CREB activity has been linked positively to vasculoprotection 26 and CREB is a direct downstream target of AMPK 27, 28 . Treatment of HUVEC with celecoxib resulted in a 2-3-fold increase in CREB Ser133 phosphorylation after 15-30 mins (Fig. 4A) . A DNA-binding ELISA further demonstrated CREB activation, with a significant 2-fold increase in CREB DNA binding seen following celecoxib treatment and when compared to the vehicle control. The specificity of this response was demonstrated by its complete suppression in the presence of a wild-type competitive oligonucleotide corresponding to the CRE consensus sequence (p < 0.01, Fig. 4B ).
Silencing AMPKα prior to celecoxib treatment prevented the 3-fold increase in CREB phosphorylation (p < 0.01), suggesting that AMPKα acts upstream of CREB in HUVEC ( Fig. 4C ). siRNA oligonucleotides were used to demonstrate the functional role of CREB. Celecoxib had no effect on total CREB, while CREB-specific siRNA depleted the protein by up to 90% (Supplementary Figure 2 ). Loss of CREB abrogated the induction of HO-1 mRNA and protein by celecoxib (p < 0.01, Fig. 4D ,E), further supporting the presence of an AMPK-CREB-dependent pathway. Moving away from venous EC, this pathway was also activated in human arterial EC (HAEC) following treatment with celecoxib. A 2-fold increase in phospho-AMPK Thr172 and a 3-fold increase in phospho-CREB Ser133 were seen following 15 and 30 mins exposure respectively ( Fig. 4F ). Likewise, treatment of HAEC with celecoxib for 24 h increased HO-1 protein by up to 3-fold (p < 0.001, Fig. 4G ).
Nrf2 acts downstream of celecoxib in the vascular endothelium. Transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a central role in the regulation of HO-1 29 . Activation of Nrf2 is accompanied by its translocation to the nucleus and binding to anti-oxidant response elements (ARE) in target promoters. Nrf2 was confined to the cytoplasm in vehicle-treated HUVEC, while 64.8 ± 4.9% localised to the nucleus following treatment with celecoxib ( Fig. 5A ). Confocal imaging analysis of Nrf-2 nuclear fluorescence intensity confirmed that this response was AMPK-dependent, with AMPK silencing significantly attenuating Nrf2 nuclear translocation (p < 0.01, Fig. 5B ). Nrf2 siRNA oligonucleotides were able to reduce HUVEC Nrf2 protein by up to 80% (Supplementary Figure 2D ). Depletion of Nrf2 reduced basal HO-1 mRNA and protein levels and completely abrogated the celecoxib-induced increase in HO-1 seen in control siRNA-transfected cells (p < 0.01, Fig. 5C ,D).
To explore further the downstream effect of Nrf2 activation by celecoxib, changes in the expression of four Nrf2 targets: H-ferritin, NAD(P)H dehydrogenase [quinone] 1 (NQO1); thioredoxin reductase 1 (Txnrd1) and thioredoxin were sought. Initial analyses demonstrated differential effects on these target genes with 4-fold and 1.5-fold increases in H-ferritin and Txnrd1 mRNA levels respectively following celecoxib treatment, and no change in either NQO1 or thioredoxin (Supplementary Figure 3A Subsequent experiments utilising control and specific siRNAs confirmed the role of Nrf2 in celecoxib-mediated induction of H-ferritin, with complete abrogation of the response following Nrf2 silencing (p < 0.01, Fig. 5F ). Likewise dependence upon AMPK-CREB signalling was similarly demonstrated (p < 0.01, Fig. 5G ,H). The role of AMPK, CREB (not shown) and Nrf2 was also confirmed in the more modest induction of Txnrd1 ( Supplementary Figure 3C ,D). Of note, Nrf2 activation alone is not sufficient to activate CREB, as sulforaphane treatment failed to induce CREB phosphorylation. In contrast, forskolin treatment, used as a positive control activated CREB (Supplementary Figure 3E ).
In vivo regulation of HO-1 and H-ferritin in response to celecoxib. To establish whether endothelial
HO-1 and H-ferritin were altered by celecoxib dosing in vivo, C57Bl/6 mice were fed normal chow or a modified mRNA by qRT-PCR. All data are derived from 4 independent experiments, normalized to vehicle-treated cells and expressed as the mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, using the two-way ANOVA or a onesample t-test. (E) Immunoblots shown have been cropped to conserve space, please see Supplementary file for original uncropped blots.
SCIENTIFIC REPORTS | (2018) 8:6271 | DOI:10.1038/s41598-018-24548-z celecoxib-supplemented chow containing 1000 ppm celecoxib for 48 hours. Selection of the celecoxib concentration in the diet was based on previous studies demonstrating that the mean maximum plasma concentration achieved after a single dose of celecoxib in humans (1.53 µg/ml) 30 can be achieved in mice receiving this diet 31, 32 . Initial experiments confirmed the efficacy of this regimen by measuring serum prostaglandin E 2 (PGE 2 ) levels 33 . After 48 hours of celecoxib-treatment the PGE 2 serum concentration fell from 107.7 ± 4.6 ng/ml to 60.4 ± 4.2 ng/ ml when compared to control mice (p < 0.05, Supplementary Figure 4A ).
Transverse sections of the descending aorta were analysed using confocal immunofluorescence microscopy. In the control animals HO-1 was detectable in vascular smooth muscle cells, but not in the aortic endothelium of sequential sections in which the endothelium was identified by staining for CD31. In contrast, aortas from celecoxib-treated animals showed induction of HO-1 in the CD31 + endothelium lining the descending aorta, with an MFI 4-fold higher than untreated controls (p < 0.01, Fig. 6A ). Similar experiments were performed using an antibody recognising H-ferritin. H-ferritin was barely detectable in the arterial wall of control mice aortas. However, in those animals exposed to celecoxib there was a 5-6-fold increase in the expression of H-ferritin in the vascular endothelium (p < 0.01, Fig. 6B ).
Celecoxib attenuates TNF-α-mediated signalling via AMPK activation and NF-κB inhibition.
To investigate the COX-2-independent functional effects of celecoxib, HUVEC were treated with celecoxib or vehicle for 24 h prior to exposure to TNF-α for 6 h and analysis of VCAM-1 mRNA by qRT-PCR. The marked induction of VCAM-1 mRNA by TNF-α was reduced by up to 30% by celecoxib (p < 0.05, Fig. 7A ). Similarly To investigate these responses further the impact of Nrf2 activity on the regulation of NF-κB p65 (RelA) was explored. As shown in Fig. 7E , TNF-α markedly increased the nuclear localisation of p65 from 3.5 ± 1.3% to 96.5 ± 1.2%, a response reduced to 34.3 ± 1.5% by celecoxib pre-treatment (p < 0.01). Nuclear translocation of p65 follows TNF-α-induced phosphorylation at Ser 536 , and celecoxib reduced this by up to 50% from 7.72 ± 0.5 to 4.11 ± 0.5-fold (p < 0.01, Fig. 7F ). However, following siRNA silencing of Nrf2 the inhibition by celecoxib was attenuated, falling to 23.9% and no longer reached significance Fig. 7F .
In light of the demonstration that AMPK activity can interfere with NF-κB signalling 34 , its role in the anti-inflammatory actions of celecoxib was also explored. In these experiments Compound C proved to be the optimal means for inhibition of AMPK. Initial attempts using AMPK siRNA led to variable results between experiments. Dosing with Compound C (5 µM) was sufficient to significantly attenuate AMP phosphorylation and the protocol used reduced the duration of each experiment leading to improved consistency between experiments. TNF-α increased p65 Ser536 phosphorylation by 11-fold and AMPK inhibition increased this by 30%. The presence of celecoxib significantly attenuated p65 phosphorylation, reducing it by 55%, a response that was completely reversed by Compound C (p < 0.01, Fig. 8A ).
Turning to the functional consequences of AMPK-mediated inhibition of NF-κB, further experimentation suggested that activation of AMPK by celecoxib is required for its suppression of VCAM-1 induction by TNF-α. VCAM-1 upregulation was suppressed by celecoxib (TNF-α 74.4 ± 2.3-fold and TNF-α + celecoxib 45.3 ± 1.4-fold) and this change was reversed by Compound C (p < 0.01, Fig. 8B ). Although these data are suggestive of a central role for AMPK, Compound C is not specific for AMPK and hence AMPK-independent actions cannot be completely excluded 35 .
Mechanistically, induction of HO-1 was responsible, at least in part, for the inhibition of VCAM-1 by celecoxib. The induction of VCAM-1 in control siRNA transfected cells was significantly reduced by celecoxib from 66.2 ± 2.2-fold to 43.4 ± 1.3-fold. However, when HO-1 was silenced the anti-inflammatory action of celecoxib was abrogated ( Fig. 8C) .
To explore the anti-inflammatory actions of celecoxib in the endothelium more widely, the pro-inflammatory effect of IL-1β was explored, using induction of IL-6 as an end-point. Treatment of HUVEC with IL-1β resulted in a 3-fold increase in IL-6 mRNA. The presence of celecoxib was able to reduce this response by 33% from 3.20 ± 0.1 to 2.06 ± 0.14-fold (p < 0.05, Fig. 8D ). Once again, inhibition of AMPK activity by Compound C completely reversed the anti-inflammatory action of celecoxib (IL-1β 3.5 ± 0.13-fold; IL-1β + celecoxib 2.2 ± 0.16-fold; and IL-1β+ celecoxib + Compound C 3.9 ± 0.17-fold) (p < 0.01, Fig. 8E ). Thus, celecoxib activates an AMPK-CREB-Nrf2-dependent pathway which exerts COX-2-independent anti-inflammatory effects on the vascular endothelium through inhibition of TNF-α and IL-1β signalling (Fig. 9 ).
Discussion
The ability of celecoxib to exert vasculoprotective effects 36, 37 may reflect in part anti-inflammatory, anti-oxidant actions upon macrophages and the vascular endothelium 20, 21 . Activation of PI-3K/Akt, enhanced redox signalling and inhibition of JNK MAPK by celecoxib have been reported 18, 20, 21 . By comparing celecoxib with DMC and nsNSAIDS, we have now identified further COX-2-independent downstream targets of celecoxib within human vascular EC. Celecoxib activates AMPK-CREB-Nrf2-dependent signalling to enhance vascular protection in the endothelium via induction of HO-1, H-ferritin and Txnrd1. Single dosing of celecoxib in humans achieves a plasma cMax of approximately 2-8 μM 30, 38 . Optimal in vitro responses were seen with 10 μM celecoxib, and this may reflect in part the extensive protein binding properties of the drug 31 . To pursue these observations' an in vivo dosing regimen was chosen that achieves plasma concentrations in mice equivalent to those seen in humans 31, 32 .
In vivo dosing of celecoxib increased EC expression of both HO-1 and H-ferritin. The novel COX-2-independent pathway played a role in the anti-inflammatory actions of celecoxib including suppression of VCAM-1 upregulation by TNF-α, and IL-1β-mediated induction of IL-6.
Concern remains about the atherothrombotic risk associated with the clinical use of anti-inflammatory drugs and particularly the COXIBs 2 . However, nsNSAIDs and COXIBs should be considered as individual agents rather than as drug classes. The recently reported SCOT and PRECISION trials found no increased cardiovascular risk when comparing celecoxib with nsNSAIDs including naproxen and ibuprofen 14, 15 , while the latest large meta-analysis suggests that the inclusion of rofecoxib has skewed the COXIB cardiovascular data 8 .
We investigated the hypothesis that the differences between the cardiovascular effects of individual nsNSAIDs and COXIBs reflect their COX-2-independent actions. The starting point was our observation that while celecoxib can induce the expression of HO-1 in human endothelium, this response was not seen with rofecoxib 20 . This action of celecoxib allowed direct comparison with DMC, a structural analogue of celecoxib generated to lack COX-2 inhibition 22 . These initial experiments (Figs 1 and 2) revealed directly comparable results between celecoxib and DMC in terms of HO-1 induction, so confirming the COX-2-independent nature of the response. Furthermore, neither naproxen nor ibuprofen was able to reproduce HO-1 induction.
An emerging relationship between AMPK and Nrf2 led us to explore this pathway in endothelial responses to celecoxib. AICAR, berberine and xanthohumol treatment of HUVEC, macrophages or fibroblasts leads to AMPK-dependent induction of HO-1 via activation of the transcription factor Nrf2 23, 39, 40 . Moreover, potent anti-inflammatory actions were observed in LPS-treated mice following activation of this pathway by berberine 39 . Celecoxib and DMC treatment of EC led to AMPK activation as evidenced by its phosphorylation at Thr 172 . In contrast, naproxen and ibuprofen failed to activate AMPK. Subsequent loss of function experiments revealed the AMPK-dependence of celecoxib-mediated HO-1 induction, Nrf2 activation and nuclear translocation.
AMPK, a heterotrimeric complex that acts as a critical metabolic regulator capable of responding to cellular stress 41 , plays an important role in endothelial metabolism and homeostasis 42 is associated with oxidative stress and endothelial dysfunction 28, 42 , while selective activation of AMPK in the vascular endothelium protects against the harmful effects associated with diabetes mellitus through induction of HO-1 43 . Thus, the finding that celecoxib is able to activate both AMPK and Nrf2 brings together redox and metabolic signalling, a combination that may help to minimise cardiovascular risk in patients.
CREB was constitutively expressed in both HUVEC and HAEC and activated by celecoxib as evidenced by phosphorylation of Ser 133 in its kinase-inducible domain and increased binding to a CRE consensus sequence. Silencing of CREB attenuated HO-1 induction by celecoxib. CREB is a direct target of AMPK and its activation is considered vasculoprotective. CREB contributes to the regulation of cell metabolism, differentiation and survival 44 , and targeted inhibition in the heart predisposes to mitochondrial dysfunction, leading to oxidative stress and increased mortality 45 . Early aortic depletion of CREB is reported in rodent models of vascular disease 26 .
The combined data suggest that celecoxib has the potential to impart vasculoprotective effects via a COX-2-independent molecular mechanism comprising 3 signalling components, all of which have their own cytoprotective actions. Initial investigation of the broader downstream effects of the AMPK-CREB-Nrf2 pathway focused on additional Nrf2 targets. Selective effects were seen with H-ferritin, Txnrd1 and HO-1 induced, while there was no change in either NQO1 or thioredoxin. This observation may reflect cell-specific effects and/or competition for Nrf2 binding at individual promoters. The most marked response to celecoxib was seen with HO-1 and H-ferritin and this was reproduced in vivo, with a 4-6-fold increase in endothelial expression seen in the murine aorta.
AMPK-Nrf2 signalling has been linked to the regulation of H-ferritin in T lymphocytes 46 . H-ferritin is widely expressed and plays a central role in the handling and storage of intracellular iron 47 . H-ferritin acts as a catalyst for the conversion of Fe 2+ to Fe 3+ and, along with L-ferritin, exerts an anti-oxidant action by removing excess free iron. A close functional relationship exists between H-ferritin and HO-1, including evidence suggesting that H-ferritin may on occasion mediate the protective effect of HO-1 against oxidative stress 48 .
The induction of VCAM-1 by TNF-α was used to initially investigate the functional effects of the celecoxib-activated AMPK-CREB-Nrf2 pathway. Pre-treatment with celecoxib or DMC significantly inhibited the induction of VCAM-1. However, neither naproxen nor ibuprofen was able to reproduce this effect. Celecoxib attenuated both phosphorylation and nuclear translocation of p65 in response to TNF-α. Experiments utilizing Compound C suggested that the inhibition of NF-κB signalling and IL-1β-mediated induction of IL-6 by celecoxib required activation of AMPK.
The outcome of the interaction between AMPK and NF-κB signalling appears to be context dependent. Thus, following activation by celecoxib, AMPK attenuated endothelial NF-κB activation by pro-inflammatory cytokines. Metformin is also reported to inhibit TNF-α-mediated activation of NF-κB via AMPK, while similarly AMPK activity attenuates fatty acid-induced p65 translocation 49, 50 . In contrast, AMPK activity induced following oxygen and glucose deprivation enhanced NF-κB signalling and protected endothelial cells against apoptosis, most likely via the induction of Bcl-2 and survivin 51 . Thus, activation of AMPK may modulate NF-κB signalling by switching the binding of p65 and/or recruitment of its co-activators away from pro-inflammatory targets to the promoters of anti-inflammatory, anti-apoptotic and anti-oxidant genes. Although the mechanism(s) underpinning such responses remains to be established, HO-1 may contribute. The reduction in VCAM-1 upregulation seen in EC pre-treated with celecoxib and exposed to TNF-α was reversed by HO-1 silencing. Moreover, HO-1 has been reported to inhibit TNF-α-induced activation of NF-κB and adhesion molecule upregulation in EC 52, 53 .
CREB and Nrf2 are members of the bZip family and we have previously suggested that transcriptional co-operation might occur between CREB1 and Nrf2 to optimise HO-1 induction 54 . Similarly heterodimerization between Nrf2 and another bZip family member ATF4, facilitates the induction of HO-1 by cadmium chloride 55 . Further experiments sought to investigate whether Nrf2 and CREB were acting in combination. Direct activation of Nrf2 in HUVECs with sulforaphane failed to phosphorylate CREB, suggesting that following activation, Nrf2 and CREB were acting in parallel ( Fig. 9 ). Silencing of Nrf2 partially inhibited celecoxib-mediated inhibition of TNF-α-induced p65 phosphorylation. We propose that this is likely, at least in part, to be related to the reduction in HO-1 seen in Nrf2-depleted cells. Thus, following celecoxib treatment, AMPK phosphorylation leads to activation of CREB and Nrf2-dependent pathways that may act in parallel to induce anti-inflammatory genes including HO-1 and H-ferritin. Of note, a cAMP/PKA/CREB pathway has been implicated in inhibition of p65 translocation following treatment with phosphodiesterase antagonists 56 , while in macrophages Nrf2 specifically inhibits inflammation-induced transcription mediated by p65 57 .
Conclusion
In contrast to ibuprofen and naproxen, celecoxib activates COX-2-independent AMPK-CREB-Nrf2 pathways to drive HO-1, H-ferritin and Txnrd1 expression in human EC. This response results in significant anti-inflammatory effects including inhibition of TNF-α-mediated NF-κB signalling, and IL-1β induction of IL-6. We propose that this and other COX-2-independent actions help to minimise adverse effects in the vasculature and contribute to the observation that celecoxib improves endothelial function in those with coronary artery disease 36 and hypertension 37 . Recent data suggests that the cardiovascular risk associated with standard dose celecoxib is not inferior to nsNSAIDS and that overall risk in patients with arthritis is very low, even in those with ischaemic heart disease 8, 10, 11, 14, 15 . In light of this, guidelines should now refocus attention of physicians to consideration of the relative risk of both cardiovascular and gastrointestinal side-effects for each patient when prescribing NSAIDs. Additional mechanistic data concerning the vasculoprotective actions of individual drugs including celecoxib is required and will ultimately lead to development of safer and more effective anti-inflammatory therapies.
Materials and Methods
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Reagents and antibodies. Monoclonal antibodies (mAb) against HO-1 and phospho-p65 Ser536
were from Abcam (Cambridge, UK). E-selectin mAb 1.2B6, ICAM-1 mAb 6.5B5 and VCAM-1 mAb 1.4C3 were generated in house. CD31 mAb P2B1 was generated in house from a clone purchased from Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA. The following antibodies were purchased from Cell Signaling (Danvers, MA) AMPKα, phospho-AMPKα Thr172 , CREB, phospho-CREB Ser133 . Antibodies against p65 and Nrf2 were from Santa Cruz Biotechnology (Heidelberg, Germany), α-tubulin Sigma-Aldrich (Poole, UK) and GAPDH Millipore (Watford, UK). 2,5-Dimethyl-celecoxib was synthesized as described 58 . Celecoxib was purchased from Toronto Research Chemicals (Ontario, Canada), naproxen and ibuprofen from Tocris Bioscience (Bristol, UK). The concentrations of all three drugs used in vitro (celecoxib 1-10 µM, naproxen and ibuprofen 1-100 μM) included concentrations that can be achieved therapeutically in humans 30, 38, 59, 60 . 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and Compound C were from Millipore, hemin and sulforaphane from Sigma-Aldrich, TNFα and IL-1β from R and D Systems (Abingdon, UK).
Endothelial cells. Use of human EC was approved by Hammersmith Hospitals Research Ethics Committee
(ref no. 06/Q0406/21). Informed consent was obtained and all experiments were performed in accordance with relevant guidelines and regulations. Human umbilical vein endothelial cells (HUVEC) were isolated by collagenase Type II digestion. Human aortic EC (HAEC) were purchased from Promocell, (Heidelberg, Germany). HUVEC and HAEC were propagated in M199 medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 20% FCS, and 30 μg/ml heparinized endothelial cell growth factor (ECGF) (all from Sigma-Aldrich). Experiments were performed with passage 3-5 EC from at least three separate isolates, plated in M199/2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 10% FCS, and 7.5 μg/ml ECGF. Pharmacological antagonists were added to the endothelial culture medium 30-60 min before celecoxib.
Cell viability assay.
HUVECs monolayers were treated with celecoxib, DMC or vehicle for 24 h. Cell viability was analysed by incubation with 20% 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in a growth factor-free medium for 3 h. Plates were read on a Synergy HT plate reader and the number of viable cells determined by measuring the absorbance at 490 nm. The si-GENOME Non-Targeting siRNA #1 from Dharmacon containing 4 mismatches to any human, mouse or rat gene was used as a negative control.
Quantitative real-time PCR. Quantitative real-time PCR (qRT-PCR) was performed using the CFX96 Real-Time system and C1000 Thermal cycler (Bio-Rad, Hercules, CA), with data calculated in relation to housekeeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). RNA was extracted from HUVEC using the RNeasy mini kit (Qiagen) and quantified at 260/280 nm using a Nanodrop 2000 spectrophotometer (Thermo Scientific, UK). 1 μg of DNase-1-digested total RNA was reverse transcribed into cDNA using 1 μM oligo(dT) and Superscript reverse transcriptase (Invitrogen, Paisley, UK). cDNA was amplified in a 25 μl reaction solution containing 5 μl of cDNA template, 12.5 μL of iSYBR supermix, 0.5 pM sense and antisense gene-specific primers, and double distilled water (dd H 2 O). The cycling parameters were 5 min at 94 °C, 35 cycles at 95 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec. The primer sequences used are listed in Supplementary Table 1 .
Adenoviral infection.
Adenoviruses encoding constitutively-active AMPK (AdCA-AMPK) (a gift from David Carling, Imperial College London) or green fluorescent protein (Ad-GFP) were amplified in HEK293A cells. Virus particles were purified according to manufacturers' instructions using the AdEasyTM Virus Purification Kit (Stratagen, La Jolla, CA). Titrations were performed using the Adeno-XTM Rapid Titer Kit (Clontech Laboratories Inc., Mountain View, CA). Following optimisation experiments, HUVECs were infected at a multiplicity of infection (MOI) of 100 viral particles/cell in plain M199 at 37 °C for 2 h. The cells were then cultured for 24 h in M199/10% FCS and 7.5 μg/mL ECGF.
CREB activation assay.
A CREB (Phospho-Ser 133 ) transcription factor assay kit (Cayman Chemicals, Cambridge, UK) was used to determine the transcriptional activation of CREB as per the manufacturers' instructions. Nuclear extracts (10 μg) were added to a 96-well plate pre-coated with a specific double-stranded DNA (dsDNA) consensus sequence containing the cAMP response element (CRE) and incubated for 1 h at r/t. A wild-type oligonucleotide was used as a binding competitor. Unstimulated Hela nuclear extract was used as a positive control. The primary antibody was directed against phospho-CREB Ser 133 and an HRP-conjugated secondary Ab was added to provide a sensitive colorimetric read-out at 450 nm Immunoblotting. EC were lysed in RIPA buffer (Sigma-Aldrich), containing a complete phosphatase and protease inhibitor (Roche, Burgess Hill, UK) at 4 °C for 15 minutes. 15 μg of protein was mixed with 7.5 μl of 4x NuPAGE ® LDS Sample Buffer (Invitrogen) and 2 μl of DL-Dithiothreitol Solution (Sigma), and the sample boiled, prior to SDS-PAGE separation and transfer onto polyvinylidene difluoride membranes (Millipore, Massachusetts) using a semi-dry blotting apparatus (Bio-Rad). Membranes were blocked with 5% BSA and incubated with primary antibodies overnight at 4 °C. Following washing, membranes were incubated with a horseradish-peroxidase-conjugated secondary Ab diluted in 5% BSA, washed and developed using chemiluminescence ECL plus (GE Healthcare, UK) and exposed to Biomax light film (Kodak, Watford, UK). Densitometry of the protein bands was performed using ImageJ v1.45 Software (National Institute of Health, USA) and expressed relative to housekeeping proteins α-tubulin and GAPDH. Nuclear translocation studies. HUVECs were fixed in ice-cold methanol for 10 min, blocked with PBS/5% BSA and incubated at 4 °C overnight with rabbit anti-Nrf2 (1:200), rabbit anti-p65 (1:200) or negative control rabbit Ig fraction (DAKO), followed by washing and addition of either AlexaFluor goat anti-rabbit 488 (Invitrogen) or AlexaFluor donkey anti-rabbit 594 (Invitrogen) for 1 h at room temperature. Slides were washed, stained with Draq5 and mounted using Vectashield (Vector Laboratories, Peterborough, UK). Nuclear translocation was analysed using a Zeiss LSM META confocal microscope, with images obtained at 40× magnification from ten random fields of view. Fluorescence intensity of Nrf2 and p65 was quantified after correction for autofluoresence and defining threshold intensity from background fluorescence.
Animals. Mice were housed in microisolator cages under controlled climactic conditions with autoclaved bedding. Irradiated food and drinking water were freely available. All animals were studied according to the guidelines from Directive 2010/63/EU of the European Parliament, with ethical approval from Imperial College London under UK Home Office Licence number PPL 70/7555. Female 8 week old C57BL/6 mice were fed for 48 hours on the standard laboratory diet (Harlan Teklad Global 18% Protein Rodent Diet, 2018) a modified celecoxib-supplemented form of the diet containing 1000 ppm celecoxib (Harlan) for 48 hours 32 . This dosing regimen achieves a plasma concentration of celecoxib in mice that is equivalent to the mean plasma concentration in humans following a single dose of celecoxib (1.53 µg/ml) 30, 32 . Following treatment, mice were sacrificed by CO 2 inhalation followed by cervical dislocation. Murine descending aorta was embedded vertically in OCT Embedding Matrix (CellPath Ltd, Newton, UK) and snap frozen in supercooled methylbutane (Sigma-Aldrich). 5 µm cryostat sections (Leica Microsystems, Wetzlar, Germany) were mounted on Superfrost microscope slides (Thermo Scientific, Waltham, MA), air-dried, fixed in ice-cold acetone for 5 minutes and stored at −80 °C.
Prostaglandin E 2 ELISA. The Prostaglandin E 2 ELISA kit was from Arbor Assays (Ann Arbor, MI). 500 µl of blood was obtained from the sacrificed animals through cardiac puncture. The blood was left to coagulate for 2 h at 4 °C and then centrifuged at 14000 rpm for 15 mins. Serum was aspirated, re-centrifuged for 5 mins at 14000 rpm prior to storage at −80 °C. Samples were diluted 1:20 in assay buffer and analysed in duplicate according to the manufacturers' instructions and read at 450 nm on a Synergy HT plate reader (Bio Tek Instrument, Swindon, UK).
Immunohistochemistry. Transverse sections of frozen aorta were blocked for 1 h with 20% goat serum or 20% rabbit serum (DAKO) diluted in PBS. Polyclonal goat anti-mouse HO-1 or goat IgG isotype control (Santa Cruz) diluted 1:100 in PBS were added and incubated overnight at 4 °C. The process was repeated with polyclonal rabbit anti-mouse H-ferritin (Abcam, US) or rabbit IgG isotype control (Santa Cruz). Following washing, Alexa Fluor 568-conjugated rabbit anti-goat IgG or Alexa Fluor 546-conjugated goat anti-rabbit IgG (Invitrogen) (1:200) were added for 1 h in the dark. Slides were washed in PBS and rat anti-mouse CD31 mAb (Biolegend, SD, USA) was added as an endothelial marker and incubated for 2 h in the dark. Slides were washed and incubated with Alexa Fluor 488-conjugated goat anti-rat IgG and DAPI (4′6′-diamidino-2-phenylindole, Sigma) for 60 and 5 min respectively. Slides were mounted in Vectashield (Vector) and images captured with a Leica DM 2500 fluorescent microscope (Leica Microsystems, Wetzlar, Germany). Negative control area images were used in the calibration of green or red channel background intensity. Scan settings were set to optimise the signal/noise ratio for each emission wavelength. There was no detectable crossover between channels. Leica LAS EZ version 4.3 software was used to process the images which were quantified using ImageJ. Endothelial and adventitial areas were identified using the anti-CD31 stained co-localised image. Next, HO-1 and H-ferritin levels were quantified by recording the mean fluorescence intensity in the specific areas. The distribution of the pixel intensities in the red and green channels was computed using the histogram function. The background signal from the negative control images was subtracted.
Statistical analysis. Data were analysed using GraphPad Prism Software (San Diego, CA, USA). Numerical data are presented as the mean of at least 3 individual experiments ± standard error (SEM). As indicated in the figure legends, differences between treatments were evaluated using the following methods: a one-sample t-test to compare two columns, an unpaired Student's t-test, Mann-Whitney U test or, to evaluate three or more samples, the analysis of variance (ANOVA) was used. A Bonferroni correction was used to correct for multiple comparisons. P < 0.05 was considered significant.
